Redmile Group, LLC Cabaletta Bio, Inc. Transaction History

Redmile Group, LLC

$1.53 Billion
Q3 2024

A detailed history of Redmile Group, LLC transactions in Cabaletta Bio, Inc. stock. As of the latest transaction made, Redmile Group, LLC holds 442,826 shares of CABA stock, worth $1.05 Million. This represents 0.14% of its overall portfolio holdings.

Number of Shares

442,826

Previous 442,826 -0.0%

Holding current value

$1.05 Million

Previous $3.31 Million 36.9%

% of portfolio

0.14%

Previous 0.22%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$16.79 - $25.38 $15.6 Million - $23.6 Million	-931,363 Reduced 67.78%	442,826 $7.55 Million
Q4 2023 Feb 14, 2024	BUY	$12.21 - $23.36 $47,496 - $90,870	3,890 Added 0.28%	1,374,189 $31.2 Million
Q2 2023 Aug 14, 2023	BUY	$7.65 - $13.95 $8.38 Million - $15.3 Million	1,096,047 Added 399.65%	1,370,299 $17.7 Million
Q1 2023 May 15, 2023	SELL	$7.08 - $12.62 $1.35 Million - $2.4 Million	-190,000 Reduced 40.93%	274,252 $2.27 Million
Q4 2022 Feb 14, 2023	SELL	$0.64 - $9.3 $148,560 - $2.16 Million	-232,125 Reduced 33.33%	464,252 $4.29 Million
Q3 2021 Nov 15, 2021	SELL	$7.0 - $12.5 $7 - $12	-1 Reduced -0.0%	696,377 $8.47 Million
Q1 2021 May 17, 2021	SELL	$10.39 - $14.53 $7.09 Million - $9.91 Million	-681,941 Reduced 49.48%	696,378 $7.73 Million
Q4 2020 Feb 16, 2021	SELL	$9.81 - $15.8 $81,079 - $130,587	-8,265 Reduced 0.6%	1,378,319 $17.2 Million
Q3 2020 Nov 16, 2020	SELL	$9.71 - $14.41 $381,719 - $566,485	-39,312 Reduced 2.76%	1,386,584 $15 Million
Q1 2020 May 15, 2020	SELL	$6.0 - $18.67 $34,800 - $108,286	-5,800 Reduced 0.41%	1,425,896 $10.4 Million
Q4 2019 Feb 14, 2020	BUY	$7.88 - $17.71 $11.3 Million - $25.4 Million	1,431,696 New	1,431,696 $20 Million

Others Institutions Holding CABA

# of Institutions

126

Shares Held

47.9M

Call Options Held

202K

Put Options Held

110K

View Full List

About Cabaletta Bio, Inc.

Ticker CABA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,014,000
Market Cap $69.1M
Description
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce di...

More about CABA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Redmile Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Redmile Group, LLC with notifications on news.

Account

Redmile Group, LLC Cabaletta Bio, Inc. Transaction History